EA201690963A1 - КРИСТАЛЛИЧЕСКИЙ ИНГИБИТОР β-ЛАКТАМАЗЫ - Google Patents

КРИСТАЛЛИЧЕСКИЙ ИНГИБИТОР β-ЛАКТАМАЗЫ

Info

Publication number
EA201690963A1
EA201690963A1 EA201690963A EA201690963A EA201690963A1 EA 201690963 A1 EA201690963 A1 EA 201690963A1 EA 201690963 A EA201690963 A EA 201690963A EA 201690963 A EA201690963 A EA 201690963A EA 201690963 A1 EA201690963 A1 EA 201690963A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lactamase
crystal inhibitor
inhibitor
formula
compound
Prior art date
Application number
EA201690963A
Other languages
English (en)
Other versions
EA031348B1 (ru
Inventor
Алессандро Ламоника
Марко Фрозатти
Стефано Бьонди
Original Assignee
Аллекра Терапьютикс Сас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49818360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690963(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аллекра Терапьютикс Сас filed Critical Аллекра Терапьютикс Сас
Publication of EA201690963A1 publication Critical patent/EA201690963A1/ru
Publication of EA031348B1 publication Critical patent/EA031348B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Кристаллическое соединение формулы (I)Соединение формулы (I) представляет собой ингибитор β-лактамазы и может вводиться в комбинации с антибактериальным средством для профилактики или лечения бактериальной инфекции.
EA201690963A 2013-11-08 2014-11-07 КРИСТАЛЛИЧЕСКИЙ ИНГИБИТОР β-ЛАКТАМАЗЫ EA031348B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1319776.9A GB201319776D0 (en) 2013-11-08 2013-11-08 Compound
GBGB1408643.3A GB201408643D0 (en) 2013-11-08 2014-05-15 Compound
PCT/EP2014/074108 WO2015067787A1 (en) 2013-11-08 2014-11-07 Crystalline beta-lactamase inhibitor

Publications (2)

Publication Number Publication Date
EA201690963A1 true EA201690963A1 (ru) 2016-10-31
EA031348B1 EA031348B1 (ru) 2018-12-28

Family

ID=49818360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690963A EA031348B1 (ru) 2013-11-08 2014-11-07 КРИСТАЛЛИЧЕСКИЙ ИНГИБИТОР β-ЛАКТАМАЗЫ

Country Status (14)

Country Link
US (2) US20160289245A1 (ru)
EP (1) EP3066103A1 (ru)
JP (2) JP7045795B2 (ru)
KR (1) KR20160081964A (ru)
CN (1) CN105873935B (ru)
AU (1) AU2014345507B2 (ru)
CA (1) CA2929199C (ru)
CL (1) CL2016001097A1 (ru)
EA (1) EA031348B1 (ru)
GB (2) GB201319776D0 (ru)
IL (1) IL245386A0 (ru)
MX (1) MX2016005869A (ru)
PE (1) PE20160890A1 (ru)
WO (1) WO2015067787A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
DE69805975T2 (de) * 1997-12-29 2002-12-19 Res Corp Technologies Inc 2-beta-substituierte-6-alkylidenpenizillansäure-derivate als beta-laktamase inhibitoren
US7273935B2 (en) * 2003-08-21 2007-09-25 Orchid Chemicals & Pharmaceuticals, Ltd. Process for the preparation of 3-methylcepham derivatives
US7417143B2 (en) * 2004-04-07 2008-08-26 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of Tazobactam in pure form
PT2046802E (pt) * 2006-07-12 2013-09-12 Allecra Therapeutics Gmbh Derivados de penamo 2-substituídos com metilo
EA030662B1 (ru) * 2010-11-25 2018-09-28 Аллекра Терапойтикс Гмбх β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ
AU2013260057A1 (en) * 2012-05-07 2014-11-27 The Regents Of The University Of California Novel oxysterol analogue, Oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
US9683009B2 (en) * 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
EP3229809B1 (en) * 2014-12-09 2019-11-27 Warsaw Orthopedic, Inc. Compounds and methods involving sterols

Also Published As

Publication number Publication date
WO2015067787A1 (en) 2015-05-14
US20190071456A1 (en) 2019-03-07
AU2014345507B2 (en) 2018-11-22
US20160289245A1 (en) 2016-10-06
AU2014345507A1 (en) 2016-05-19
JP7045795B2 (ja) 2022-04-01
US11124526B2 (en) 2021-09-21
CN105873935B (zh) 2019-03-19
CL2016001097A1 (es) 2016-12-02
EA031348B1 (ru) 2018-12-28
IL245386A0 (en) 2016-06-30
CA2929199C (en) 2023-01-03
EP3066103A1 (en) 2016-09-14
JP2021102642A (ja) 2021-07-15
PE20160890A1 (es) 2016-08-25
GB201319776D0 (en) 2013-12-25
JP7346485B2 (ja) 2023-09-19
MX2016005869A (es) 2017-01-05
CN105873935A (zh) 2016-08-17
CA2929199A1 (en) 2015-05-14
GB201408643D0 (en) 2014-07-02
JP2016535054A (ja) 2016-11-10
KR20160081964A (ko) 2016-07-08

Similar Documents

Publication Publication Date Title
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
MY176797A (en) Novel pyrazol derivatives
NZ713621A (en) Compounds and methods of treating infections
MX2013011526A (es) Derivados de isoxazol utiles como agentes antibacteriales .
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
EA201391822A1 (ru) Новые производные пиридина
PH12016500225B1 (en) Novel quinoline-substituted compound
MX2012012530A (es) Derivados de n1-sulfonil-5-fluorpirimidinona.
EA201492210A1 (ru) Соединения, ингибирующие активность катехол-o-метилтрансферазы
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201690894A1 (ru) Феноксиэтилы
MX2015013629A (es) Nuevos derivados de piridina.
MX2020005533A (es) Nuevo proceso para la preparacion de derivados de piperidinilo-azetidina e intermediarios de los mismos, en donde dichos compuestos son inhibidores de mek.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
ES2721278T3 (es) Composiciones de alcaloides de la especie Ribes para tratar afecciones asociadas con la función mitocondrial o inhibición de pDE4, PDE5 e IKK-BETA
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
MX2021015514A (es) Compuesto heterociclico.
TR201901986T4 (tr) Heterosiklik bileşik.
MX2016004509A (es) Compuestos que contienen nitrogeno y su uso.
MX2015006930A (es) Compuestos de isoxazol amina sustituidos como inhibidores de scd1.
MX2015016766A (es) Nuevos derivados de tetrazolona.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM